Clinical Trials Logo

Mucopolysaccharidosis III clinical trials

View clinical trials related to Mucopolysaccharidosis III.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04201405 Active, not recruiting - Clinical trials for Mucopolysaccharidosis Type IIIA

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type IIIA

Start date: January 7, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with MPS IIIA have a clinical disorder marked by severe and progressive brain disease and neurological symptoms due to the accumulation of undigested glycosaminoglycans in all cells of the body. This study will be the first in human clinical trial to explore the safety, tolerability and clinical efficacy of ex vivo gene therapy (autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene) in MPSIIIA patients. Following treatment with the gene therapy patients will be followed up for a minimum of 3 years.

NCT ID: NCT03784287 Active, not recruiting - Clinical trials for Mucopolysaccharidosis Type IIIB

A Treatment Extension Study of Mucopolysaccharidosis Type IIIB

Start date: February 19, 2018
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to evaluate the long-term safety and tolerability of AX 250 administered to subjects with MPS IIIB by an implanted ICV reservoir and catheter and to evaluate the impact of long-term AX 250 treatment on cognitive function in patients with MPS IIIB as assessed by developmental quotient (DQ).

NCT ID: NCT03612869 Active, not recruiting - Clinical trials for Mucopolysaccharidosis Type IIIA

Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)

AAVance
Start date: December 17, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

MPS IIIA is predominantly a central nervous system disease causing cognitive disability, progressive loss of acquired skills, behavioral and sleep disturbance. LYS-SAF302 is a gene therapy which is intended to deliver a functional copy of the SGSH gene to the brain. This is a phase 2-3 study to assess the efficacy in improving or stabilizing the neurodevelopmental state of MPS IIIA patients.

NCT ID: NCT03227042 Active, not recruiting - Clinical trials for Mucopolysaccharidosis Type IIIB

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Start date: November 16, 2017
Phase:
Study type: Observational

This is a natural history study for children up to 18 years of age who have been diagnosed with Mucopolysaccharidosis Type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B). Mucopolysaccharidosis type IIIB is a severe neurodegenerative disorder. The information gathered from this trial may help inform the design and interpretation of subsequent interventional studies. No clinical intervention or study drug is provided by Allievex in this study.

NCT ID: NCT02716246 Active, not recruiting - Sanfilippo Syndrome Clinical Trials

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

Start date: March 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The main objective of this study is to evaluate the efficacy and safety of ABO-102 for the treatment of MPS IIIA.